Stroke in Mechanical Circulatory Supported Cardiogenic Shock

Abstract

Stroke is a devastating and underdiagnosed complication in patients with cardiogenic shock (CS) supported by temporary mechanical circulatory support (tMCS). Stroke occurs in approximately 1 to 4% of patients on microaxial flow pumps and 6 to 7% of those on veno-arterial extracorporeal membrane oxygenation, though the true incidence is likely higher due to diagnostic limitations in sedated and critically ill patients. The occurrence of stroke in this population significantly worsens clinical outcomes, increasing morbidity, mortality, and healthcare resource utilization. This review outlines the risk factors and mechanisms underlying both ischaemic and haemorrhagic stroke in patients receiving tMCS. It explores how the aetiology of CS, the choice of tMCS device, anticoagulation strategies, and cellular injury contribute to stroke risk. The pathophysiology in this setting is multifactorial and often dual-edged, driven by haemolysis, platelet dysfunction, endothelial disruption, and immune-mediated thrombogenesis. Concurrently, bleeding complications arise from acquired von Willebrand syndrome, thrombocytopenia, and dysregulated fibrinolysis. Currently, there are no evidence-based guidelines for managing bleeding and thrombotic complications in patients on tMCS, largely due to the lack of robust data. Consequently, clinical practices vary, and treatment decisions often require navigating a complex balance between thrombosis and bleeding without high-quality evidence to guide care. This review highlights the key physiological and pathological changes associated with tMCS to inform strategies for stroke prevention, early detection, and management. Developing standardised protocols through prospective studies is essential to improving outcomes in this high-risk population.

Keywords

cardiogenic shock - mechanical circulatory support - stroke

Publikationsverlauf

Eingereicht: 19. März 2025

Angenommen: 07. September 2025

Artikel online veröffentlicht:
18. September 2025

• References

• 1 van Diepen S, Katz JN, Albert NM. et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation 2017; 136 (16) e232-e268
• 2 Møller JE, Engstrøm T, Jensen LO. et al; DanGer Shock Investigators. Microaxial flow pump or standard care in infarct-related cardiogenic shock. N Engl J Med 2024; 390 (15) 1382-1393
• 3 Lüscher TF, Thiele H. Cardiogenic shock: do we need a paradigm shift?. Eur Heart J 2024; 45 (39) 4178-4180
• 4 Thiele H, Zeymer U, Akin I. et al; ECLS-SHOCK Investigators. Extracorporeal life support in infarct-related cardiogenic shock. N Engl J Med 2023; 389 (14) 1286-1297
• 5 Hwang J, Kalra A, Shou BL. et al. Epidemiology of ischemic stroke and hemorrhagic stroke in venoarterial extracorporeal membrane oxygenation. Crit Care 2023; 27 (01) 433
• 6 Pahuja M, Chehab O, Ranka S. et al. Incidence and clinical outcomes of stroke in ST-elevation myocardial infarction and cardiogenic shock. Catheter Cardiovasc Interv 2021; 97 (02) 217-225
• 7 Rastan AJ, Lachmann N, Walther T. et al. Autopsy findings in patients on postcardiotomy extracorporeal membrane oxygenation (ECMO). Int J Artif Organs 2006; 29 (12) 1121-1131
• 8 Levy JH, Alexander PMA, Wolberg AS. et al. ECMO-induced coagulopathy: strategic initiatives for research and clinical practice (a workshop report of the NHLBI). Blood Vessel Thromb Hemost 2025; 2 (02) 100064
• 9 Pacheco-Reyes AF, Plata-Menchaca EP, Mera A. et al. Coagulation management in patients requiring extracorporeal membrane oxygenation support: a comprehensive narrative review. Ann Blood 2024; 9
• 10 Bae DJ, Willey JZ, Ibeh C, Yuzefpolskaya M, Colombo PC. Stroke and mechanical circulatory support in adults. Curr Cardiol Rep 2023; 25 (12) 1665-1675
• 11 Stone GW, Ohman EM, Miller MF. et al. Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry. J Am Coll Cardiol 2003; 41 (11) 1940-1945
• 12 Thiele H, Zeymer U, Neumann F-J. et al; IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367 (14) 1287-1296
• 13 Motia N, Marko V, Karlsen MW. Complications associated with intra-aortic balloon pump treatment in critically ill patients: a systematic review. Nurs Crit Care 2024; 29 (06) 1768-1780
• 14 Ouweneel DM, de Brabander J, Karami M. et al. Real-life use of left ventricular circulatory support with Impella in cardiogenic shock after acute myocardial infarction: 12 years AMC experience. Eur Heart J Acute Cardiovasc Care 2019; 8 (04) 338-349
• 15 Saito Y, Tateishi K, Toda K, Matsumiya G, Kobayashi Y. J-PVAD registry study investigators. Complications and outcomes of Impella treatment in cardiogenic shock patients with and without acute myocardial infarction. J Am Heart Assoc 2023; 12 (17) e030819
• 16 Ramzy D, Anderson M, Batsides G. et al. Early outcomes of the first 200 US Patients treated with Impella 5.5: a novel temporary left ventricular assist device. Innovations (Phila) 2021; 16 (04) 365-372
• 17 Rock JR, Kos CA, Lemaire A. et al. Single center first year experience and outcomes with Impella 5.5 left ventricular assist device. J Cardiothorac Surg 2022; 17 (01) 124
• 18 Le Guennec L, Cholet C, Huang F. et al. Ischemic and hemorrhagic brain injury during venoarterial-extracorporeal membrane oxygenation. Ann Intensive Care 2018; 8 (01) 129
• 19 Cho SM, Canner J, Caturegli G. et al. Risk factors of ischemic and hemorrhagic strokes during venovenous extracorporeal membrane oxygenation: analysis of data from the Extracorporeal Life Support Organization Registry. Crit Care Med 2021; 49 (01) 91-101
• 20 Cho SM, Canner J, Chiarini G. et al. Modifiable risk factors and mortality from ischemic and hemorrhagic strokes in patients receiving venoarterial extracorporeal membrane oxygenation: results from the Extracorporeal Life Support Organization Registry. Crit Care Med 2020; 48 (10) e897-e905
• 21 Schrage B, Becher PM, Bernhardt A. et al. Left ventricular unloading is associated with lower mortality in patients with cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation: results from an international, multicenter cohort study. Circulation 2020; 142 (22) 2095-2106
• 22 Yan R, Yang J, Shi B. et al. Risk of acute ischemic stroke with early versus late initiation of mechanical circulatory support in hospitalizations with acute myocardial infarction complicated by cardiogenic shock: a propensity-matched analysis. BMC Cardiovasc Disord 2025; 25 (01) 372
• 23 Barrionuevo-Sánchez MI, Ariza-Solé A, Prado ND. et al. Impact of shock aetiology and hospital characteristics on the clinical profile, management and prognosis of patients with non ACS-related cardiogenic shock. Hellenic J Cardiol 2023; 69: 16-23
• 24 Noda K, Koga M, Toyoda K. Recognition of strokes in the ICU: a narrative review. J Cardiovasc Dev Dis 2023; 10 (04) 182
• 25 Jo S, Chang JY, Jeong S, Jeong S, Jeon SB. Newly developed stroke in patients admitted to non-neurological intensive care units. J Neurol 2020; 267 (10) 2961-2970
• 26 Schupp T, Forner J, Rusnak J. et al. Does atrial fibrillation deteriorate the prognosis in patients with septic or cardiogenic shock?. Am J Cardiol 2023; 205: 141-149
• 27 de Waha S, Schoene K, Fuernau G. et al. Prognostic impact of atrial fibrillation in cardiogenic shock complicating acute myocardial infarction: a substudy of the IABP-SHOCK II trial. Clin Res Cardiol 2018; 107 (03) 233-240
• 28 Deng RM, Liu YC, Li JQ, Xu JG, Chen G. The role of carbon dioxide in acute brain injury. Med Gas Res 2020; 10 (02) 81-84
• 29 Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch 2007; 454 (03) 345-359
• 30 Alphonsus CS, Rodseth RN. The endothelial glycocalyx: a review of the vascular barrier. Anaesthesia 2014; 69 (07) 777-784
• 31 Coster JN, Noda K, Ryan JP. et al. Effects of intraoperative support strategies on endothelial injury and clinical lung transplant outcomes. Semin Thorac Cardiovasc Surg 2024; 36 (03) 358-368
• 32 Chen X, Geng X, Jin S. et al. The Association of Syndecan-1, hypercoagulable state and thrombosis and in patients with nephrotic syndrome. Clin Appl Thromb Hemost 2021; 27: 10 760296211010256
• 33 Horvath B, Hegedus D, Szapary L. et al. Measurement of von Willebrand factor as the marker of endothelial dysfunction in vascular diseases. Exp Clin Cardiol 2004; 9 (01) 31-34
• 34 Ernofsson M, Thelin S, Siegbahn A. Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study. J Thorac Cardiovasc Surg 1997; 113 (03) 576-584
• 35 Doyle AJ, Hunt BJ. Current understanding of how extracorporeal membrane oxygenators activate haemostasis and other blood components. Front Med (Lausanne) 2018; 5: 352
• 36 Vandenbriele C, Vanassche T, Price S. Why we need safer anticoagulant strategies for patients on short-term percutaneous mechanical circulatory support. Intensive Care Med 2020; 46 (04) 771-774
• 37 Zhou Y, Qin S, Hilton T. et al. Quantification of Von Willebrand factor cleavage by ADAMTS-13 in patients supported by left ventricular assist devices. ASAIO J 2017; 63 (06) 849-853
• 38 Staessens S, Moussa MD, Pierache A. et al. Thrombus formation during ECMO: Insights from a detailed histological analysis of thrombus composition. J Thromb Haemost 2022; 20 (09) 2058-2069
• 39 Hastings SM, Deshpande SR, Wagoner S, Maher K, Ku DN. Thrombosis in centrifugal pumps: location and composition in clinical and in vitro circuits. Int J Artif Organs 2016; 39 (04) 200-204
• 40 Hastings SM, Ku DN, Wagoner S, Maher KO, Deshpande S. Sources of circuit thrombosis in pediatric extracorporeal membrane oxygenation. ASAIO J 2017; 63 (01) 86-92
• 41 Bannan S, Danby A, Cowan D, Ashraf S, Gesinde M, Martin P. Cell activation and thrombin generation in heparin bonded cardiopulmonary bypass circuits using a novel in vitro model. Eur J Cardiothorac Surg 1997; 12 (02) 268-275
• 42 Balla G, Jacob HS, Eaton JW, Belcher JD, Vercellotti GM. Hemin: a possible physiological mediator of low density lipoprotein oxidation and endothelial injury. Arterioscler Thromb 1991; 11 (06) 1700-1711
• 43 Lin T, Kwak YH, Sammy F. et al. Synergistic inflammation is induced by blood degradation products with microbial Toll-like receptor agonists and is blocked by hemopexin. J Infect Dis 2010; 202 (04) 624-632
• 44 Tran PL, Pietropaolo M-G, Valerio L. et al. Hemolysate-mediated platelet aggregation: an additional risk mechanism contributing to thrombosis of continuous flow ventricular assist devices. Perfusion 2016; 31 (05) 401-408
• 45 Frere C, Mazzeffi M, Maier CL. et al. Acquired von Willebrand syndrome during extracorporeal membrane oxygenation support: a comprehensive review of current evidence: communication from the ISTH SSC on perioperative and critical care thrombosis and hemostasis. J Thromb Haemost 2024; 22 (09) 2608-2628
• 46 Hanson E, Jood K, Nilsson S, Blomstrand C, Jern C. Association between genetic variation at the ADAMTS13 locus and ischemic stroke. J Thromb Haemost 2009; 7 (12) 2147-2148
• 47 Saeed O, Jakobleff WA, Forest SJ. et al. Hemolysis and nonhemorrhagic stroke during venoarterial extracorporeal membrane oxygenation. Ann Thorac Surg 2019; 108 (03) 756-763
• 48 Cowger JA, Romano MA, Shah P. et al. Hemolysis: a harbinger of adverse outcome after left ventricular assist device implant. J Heart Lung Transplant 2014; 33 (01) 35-43
• 49 Omar HR, Mirsaeidi M, Socias S. et al. Plasma free hemoglobin is an independent predictor of mortality among patients on extracorporeal membrane oxygenation support. PLoS One 2015; 10 (04) e0124034
• 50 Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13 (03) 269-288
• 51 Ridger VC, Boulanger CM, Angelillo-Scherrer A. et al; Position Paper of the European Society of Cardiology (ESC) Working Group on Atherosclerosis and Vascular Biology. Microvesicles in vascular homeostasis and diseases. Thromb Haemost 2017; 117 (07) 1296-1316
• 52 Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol 2011; 31 (01) 15-26
• 53 Siegel PM, Hentschel D, Bojti I. et al. Annexin V positive microvesicles are elevated and correlate with flow rate in patients receiving veno-arterial extracorporeal membrane oxygenation. Interact Cardiovasc Thorac Surg 2020; 31 (06) 884-891
• 54 Chandler WL. Platelet, red cell, and endothelial activation and injury during extracorporeal membrane oxygenation. ASAIO J 2021; 67 (08) 935-942
• 55 Diehl P, Aleker M, Helbing T. et al. Enhanced microparticles in ventricular assist device patients predict platelet, leukocyte and endothelial cell activation. Interact Cardiovasc Thorac Surg 2010; 11 (02) 133-137
• 56 Nascimbene A, Hernandez R, George JK. et al. Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices. J Heart Lung Transplant 2014; 33 (05) 470-477
• 57 Gupta A, Karakas C, Sukru A, Elnazeir M. Hemorrhagic complications of unfractionated heparin in adult patients with acute ischemic stroke: prevalence and risk factors (P2–5.012). Neurology 2024; 102 (07) 2690
• 58 Adams JA. Endothelium and cardiopulmonary resuscitation. Crit Care Med 2006; 34 (12, suppl): S458-S465
• 59 Cerchiari EL, Safar P, Klein E, Diven W. Visceral, hematologic and bacteriologic changes and neurologic outcome after cardiac arrest in dogs. The visceral post-resuscitation syndrome. Resuscitation 1993; 25 (02) 119-136
• 60 Neumar RW, Nolan JP, Adrie C. et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. Circulation 2008; 118 (23) 2452-2483
• 61 Engström M, Schött U, Romner B, Reinstrup P. Acidosis impairs the coagulation: a thromboelastographic study. J Trauma 2006; 61 (03) 624-628
• 62 Rossaint R, Afshari A, Bouillon B. et al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition. Crit Care 2023; 27 (01) 80
• 63 Wallner B, Schenk B, Hermann M. et al. Hypothermia-associated coagulopathy: a comparison of viscoelastic monitoring, platelet function, and real time live confocal microscopy at low blood temperatures, an in vitro experimental study. Front Physiol 2020; 11: 843
• 64 Vallabhajosyula S, Dunlay SM, Prasad A. et al. Acute noncardiac organ failure in acute myocardial infarction with cardiogenic shock. J Am Coll Cardiol 2019; 73 (14) 1781-1791
• 65 Masi P, Gendreau S, Moyon Q. et al. Bleeding complications, coagulation disorders, and their management in acute myocardial infarction-related cardiogenic shock rescued by veno-arterial ECMO: A retrospective cohort study. J Crit Care 2024; 82: 154771
• 66 Oyabu K, Hattori H, Kikuchi N. et al. Cardiogenic shock severity predicts bleeding events in patients with temporary mechanical circulatory support. Catheter Cardiovasc Interv 2024; 104 (07) 1508-1516
• 67 Freund A, Jobs A, Lurz P. et al. Frequency and impact of bleeding on outcome in patients with cardiogenic shock. JACC Cardiovasc Interv 2020; 13 (10) 1182-1193
• 68 Valladolid C, Yee A, Cruz MA. von Willebrand Factor, free hemoglobin and thrombosis in ECMO. Front Med (Lausanne) 2018; 5: 228
• 69 Panholzer B, Bajorat T, Haneya A. et al. Acquired von Willebrand syndrome in ECMO patients: A 3-year cohort study. Blood Cells Mol Dis 2021; 87: 102526
• 70 Flierl U, Tongers J, Berliner D. et al. Acquired von Willebrand syndrome in cardiogenic shock patients on mechanical circulatory microaxial pump support. PLoS One 2017; 12 (08) e0183193
• 71 Mehra MR, Goldstein DJ, Cleveland JC. et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial. JAMA 2022; 328 (12) 1233-1242
• 72 Wever-Pinzon O, Selzman CH, Drakos SG. et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail 2013; 6 (03) 517-526
• 73 Vincent F, Rauch A, Loobuyck V. et al. Arterial pulsatility and circulating von Willebrand factor in patients on mechanical circulatory support. J Am Coll Cardiol 2018; 71 (19) 2106-2118
• 74 Jiritano F, Serraino GF, Ten Cate H. et al. Platelets and extra-corporeal membrane oxygenation in adult patients: a systematic review and meta-analysis. Intensive Care Med 2020; 46 (06) 1154-1169
• 75 Klaeske K, Dieterlen MT, Eifert S. et al. Device-induced platelet dysfunction in patients after left ventricular assist device implantation. J Thromb Haemost 2021; 19 (05) 1331-1341
• 76 Houry EA, Gengler BE, Alberts JL, Van Tuyl JS. Evaluation of thrombocytopenia in patients receiving percutaneous mechanical circulatory support with an Impella device. Crit Care Explor 2022; 4 (10) e0772
• 77 Raasveld SJ, van den Oord C, Schenk J. et al. The interaction of thrombocytopenia, hemorrhage, and platelet transfusion in venoarterial extracorporeal membrane oxygenation: a multicenter observational study. Crit Care 2023; 27 (01) 321
• 78 Milwidsky A, Haroun M, Saeed O. et al. Post left ventricular assist device implantation platelets count alterations are related to gender, race and early mortality. J Heart Lung Transplant 2021; 40 (4, suppl): S400
• 79 Huang Z, Liu C, Wu Z. et al. Elevated platelet count is associated with decreased mortality from hemorrhagic stroke in hospital: a multi-center retrospective cohort study. Sci Rep 2024; 14 (01) 3797
• 80 Collins Yoder AS, Hines CB. Thrombocytopenia: effect in ischemic and hemorrhagic stroke. Dimens Crit Care Nurs 2021; 40 (03) 139-148
• 81 Chen Z, Mondal NK, Ding J, Gao J, Griffith BP, Wu ZJ. Shear-induced platelet receptor shedding by non-physiological high shear stress with short exposure time: glycoprotein Ibα and glycoprotein VI. Thromb Res 2015; 135 (04) 692-698
• 82 Siegel PM, Chalupsky J, Olivier CB. et al. Early platelet dysfunction in patients receiving extracorporeal membrane oxygenation is associated with mortality. J Thromb Thrombolysis 2022; 53 (03) 712-721
• 83 Kalbhenn J, Schlagenhauf A, Rosenfelder S, Schmutz A, Zieger B. Acquired von Willebrand syndrome and impaired platelet function during venovenous extracorporeal membrane oxygenation: rapid onset and fast recovery. J Heart Lung Transplant 2018; 37 (08) 985-991
• 84 Marquardt L, Ruf A, Mansmann U. et al. Course of platelet activation markers after ischemic stroke. Stroke 2002; 33 (11) 2570-2574
• 85 Balle CM, Jeppesen AN, Christensen S, Hvas AM. Platelet function during extracorporeal membrane oxygenation in adult patients. Front Cardiovasc Med 2019; 6: 114
• 86 Helms J, Curtiaud A, Severac F. et al. Fibrinolysis as a causative mechanism for bleeding complications on extracorporeal membrane oxygenation: a pilot observational prospective study. Anesthesiology 2024; 141 (01) 75-86
• 87 Kanou S, Nakatani E, Urano T. et al; Study of Advanced life support for Ventricular fibrillation with Extracorporeal circulation in Japan (SAVE-J II) Study Group. Fibrinogen levels and bleeding risk in adult extracorporeal cardiopulmonary resuscitation: multicenter observational study subanalysis. Res Pract Thromb Haemost 2025; 9 (02) 102700
• 88 Romoli M, Vandelli L, Bigliardi G. et al. Fibrinogen depletion coagulopathy predicts major bleeding after thrombolysis for ischemic stroke: a multicenter study. Stroke 2022; 53 (12) 3671-3678
• 89 Ribo M, Montaner J, Molina CA. et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 2004; 35 (09) 2123-2127
• 90 Doyle AJ, Retter A, Parmar K. et al. Temporal changes in markers of coagulation and fibrinolysis in adults during extracorporeal membrane oxygenation. Perfusion 2025; 40 (04) 984-992
• 91 Rilinger JF, Smith CM, deRegnier RAO. et al. Transcranial doppler identification of neurologic injury during pediatric extracorporeal membrane oxygenation therapy. J Stroke Cerebrovasc Dis 2017; 26 (10) 2336-2345
• 92 Zhang H, Xu J, Yang X. et al. Narrative review of neurologic complications in adults on ECMO: prevalence, risks, outcomes, and prevention strategies. Front Med (Lausanne) 2021; 8: 713333
• 93 Hunt MF, Clark KT, Whitman G, Choi CW, Geocadin RG, Cho SM. The use of cerebral NIRS monitoring to identify acute brain injury in patients with VA-ECMO. J Intensive Care Med 2021; 36 (12) 1403-1409
• 94 Johnston SC, Amarenco P, Denison H. et al; THALES Investigators. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med 2020; 383 (03) 207-217
• 95 Gorog DA, Combes A. Antithrombotic management during percutaneous mechanical circulatory support: defining the status quo, before agreeing quo vadis. Eur Heart J Acute Cardiovasc Care 2024; 13 (06) 470-471
• 96 Van Edom CJ, Swol J, Castelein T. et al. European practices on antithrombotic management during percutaneous mechanical circulatory support in adults: a survey of the Association for Acute CardioVascular Care of the ESC and the European branch of the Extracorporeal Life Support Organization. Eur Heart J Acute Cardiovasc Care 2024; 13 (06) 458-469
• 97 International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349 (9065): 1569-1581
• 98 Jazayeri SB, Ghozy S, Saha R, Gajjar A, Elfil M, Kallmes DF. Reevaluating the role of heparin during mechanical thrombectomy for acute ischemic stroke: Increased risks without functional benefit. Clin Neurol Neurosurg 2024; 246: 108560
• 99 Zhang X, Zhong W, Xue R. et al. Argatroban in patients with acute ischemic stroke with early neurological deterioration: a randomized clinical trial. JAMA Neurol 2024; 81 (02) 118-125
• 100 Sukumaran M, Cantrell DR, D'Agostino C, Jahromi BS, Ansari SA, Potts MB. Bivalirudin as a substitute for heparin in neurointervention for patients with heparin-induced thrombocytopenia. J Stroke Cerebrovasc Dis 2024; 33 (06) 107310
• 101 Werring DJ, Dehbi H-M, Ahmed N. et al; OPTIMAS investigators. Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial. Lancet 2024; 404 (10464): 1731-1741
• 102 To L, Attar D, Lines B. et al. Incidence of heparin-induced thrombocytopenia in patients with newly implanted mechanical circulatory support devices. Ann Pharmacother 2022; 56 (05) 565-571
• 103 Iacobelli R, Fletcher-Sandersjöö A, Lindblad C, Keselman B, Thelin EP, Broman LM. Predictors of brain infarction in adult patients on extracorporeal membrane oxygenation: an observational cohort study. Sci Rep 2021; 11 (01) 3809
• 104 Van Edom C, Fiorelli F, Balthazar T. et al. Dual guided heparin monitoring with anti-Xa and APTT during micro-axial flow pump support for cardiogenic shock. Eur Heart J 2024; 45 (01) 1758
• 105 Vandenbriele C, Mueller T, Patel B. Consumptive coagulopathy: how low-dose unfractionated heparin can prevent bleeding complications during extracorporeal life support. Intensive Care Med 2024; 50 (08) 1358-1360
• 106 Kohli G, George DD, Grenga A. et al. Mechanical thrombectomy for ischemic stroke secondary to large vessel occlusions in patients on extracorporeal membrane oxygenation. Cerebrovasc Dis 2023; 52 (05) 532-538
• 107 Le Guennec L, Schmidt M, Clarençon F. et al. Mechanical thrombectomy in acute ischemic stroke patients under venoarterial extracorporeal membrane oxygenation. J Neurointerv Surg 2020; 12 (05) 486-488
• 108 Krenzlin H, Rosenthal C, Wolf S. et al. Surgical treatment of intraparenchymal hemorrhage during mechanical circulatory support for heart-failure–a single-centre experience. Acta Neurochir (Wien) 2014; 156 (09) 1729-1734
• 109 Factora FN, Bustamante S, Spiotta A, Avitsian R. Intracranial hemorrhage surgery on patients on mechanical circulatory support: a case series. J Neurosurg Anesthesiol 2011; 23 (01) 30-34
• 110 Angiolillo DJ, Capodanno D. Uncoupling thrombosis and hemostasis by inhibiting factor XI. N Engl J Med 2025; 392 (04) 400-403